Prognose

Das durchschnittliche Kursziel der Analysten beträgt +2,89€(+261,25%). Der Median liegt bei +2,89€(+261,25%).

Kaufen	2
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company's Board of Directors granted Mary Pietryga, the Company's newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”).» Mehr auf globenewswire.com
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.» Mehr auf globenewswire.com
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC).» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Assertio Holdings einen Umsatz von 26,22 Mio€ und ein Nettoeinkommen von −2,62 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	+26,22 Mio	22,08%
Bruttoeinkommen	+19,44 Mio	27,94%
Nettoeinkommen	−2,62 Mio	99,01%
EBITDA	+4,13 Mio	102,01%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+75,99 Mio€
Anzahl Aktien	95,48 Mio
52 Wochen-Hoch/Tief	+1,73€ - +0,70€
Dividenden	Nein
Beta	0,84
KGV (PE Ratio)	−1,15
KGWV (PEG Ratio)	−0,01
KBV (PB Ratio)	+0,60
KUV (PS Ratio)	+0,63